Everzor 2.5 mg/5 mg/10 mg Tablets
PDF Leaflet Revision Date: 29 April 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment for advanced renal cell carcinoma, SEGA, advanced breast cancer, and TSC with renal angiomyolipoma.
Dosage (summary)
10 mg orally once daily; reduce to 5 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Live vaccines
Contraindications
- Hypersensitivity
- Concomitant use of live vaccines
Common side effects
- Stomatitis
- Pneumonitis
- Fatigue
- Dyspnoea
Counselling Points
- Monitor for respiratory symptoms
- Avoid live vaccines
- Use contraception during treatment
Serious warnings
- Non-infectious pneumonitis
- Increased risk of infections
- Renal failure events
Important Disclaimer
The Everzor 2.5 mg/5 mg/10 mg Tablets professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
